ABBVIE
A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice
- Conditions
- Cancer, Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 600
- Registration Number
- NCT04178317
- Locations
- 🇰🇷
Inje University - Busan Paik Hospital /ID# 233882, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Pusan National University Hospital /ID# 216850, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Kyungpook National University Hospital /ID# 233884, 중구, Daegu Gwang Yeogsi, Korea, Republic of
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
- Conditions
- Spondyloarthritis
- Interventions
- Drug: UpadacitinibDrug: Placebo
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 734
- Registration Number
- NCT04169373
- Locations
- 🇺🇸
Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 215055, Skokie, Illinois, United States
🇺🇸Arthritis & Rheumatic Disease Specialties /ID# 215306, Aventura, Florida, United States
🇨🇦Toronto Western Hospital /ID# 215041, Toronto, Ontario, Canada
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
- Conditions
- Irritable Bowel Syndrome With ConstipationFunctional Constipation
- Interventions
- Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 389
- Registration Number
- NCT04166058
- Locations
- 🇺🇸
River Birch Research Alliance /ID# 237963, Blue Ridge, Georgia, United States
🇺🇸Advanced Research Center /ID# 237960, Anaheim, California, United States
🇺🇸Dolphin Medical Research /ID# 234676, Doral, Florida, United States
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
- Conditions
- Takayasu Arteritis (TAK)
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 56
- Registration Number
- NCT04161898
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 241175, Sao Paulo, Brazil
🇯🇵Institute of Science Tokyo Hospital /ID# 214138, Bunkyo-ku, Tokyo, Japan
🇰🇷The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214566, Seoul, Seoul Teugbyeolsi, Korea, Republic of
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Cancer
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 465
- Registration Number
- NCT04161885
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214892, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇪🇸Hospital Clinic de Barcelona /ID# 215108, Barcelona, Spain
🇪🇸Hospital Santa Creu i Sant Pau /ID# 240397, Barcelona, Spain
Expanded Access to Upadacitinib
- Conditions
- Atopic Dermatitis (AD)
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04159597
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT04159779
- Locations
- 🇬🇷
University Gen Hosp of Patra /ID# 212914, Patras, Greece
🇬🇷General Hospital of Chania "Agios Georgios" /ID# 241685, Chania, Greece
🇬🇷Papageorgiou General Hospital /ID# 213710, Thessaloniki, Greece
A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.
- Conditions
- DysmenorrheaEndometriosisChronic Pelvic Pain
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 291
- Registration Number
- NCT04140175
- Locations
- 🇺🇸
Capital Women's Care - Hagerstown /ID# 217984, Hagerstown, Maryland, United States
🇺🇸Stamford Hospital /ID# 216975, Stamford, Connecticut, United States
🇺🇸Agile Clinical Research Trials /ID# 217762, Atlanta, Georgia, United States
A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
- Conditions
- HIV-1 Infection
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 239
- Registration Number
- NCT04138199
- Locations
- 🇷🇺
GBUZ Regional Center for the P /ID# 216293, Ekaterinburg, Russian Federation
🇷🇺Rep Center for the Prev and Control of AIDS and Inf Dis of the MoH of Chuvashia /ID# 216479, Cheboksary, Russian Federation
🇷🇺Reg Ctr for AIDS /ID# 216288, Chelyabinsk, Russian Federation
A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- Drug: ABBV-0805Drug: Placebo ABBV-0805
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04127695
- Locations
- 🇺🇸
University of Florida - Archer /ID# 212823, Gainesville, Florida, United States
🇺🇸Evergreen Neuroscience Institute /ID# 212827, Kirkland, Washington, United States
🇺🇸Columbia Univ Medical Center /ID# 212826, New York, New York, United States